The gut‐liver axis in nonalcoholic fatty liver disease: Another pathway to insulin resistance?
Ester Vanni, Elisabetta Bugianesi – 28 May 2009
Beyond fibrogenesis: Stellate cells take center stage as immune‐response modulators
Anand N. Bhatt, David H. Adams – 28 May 2009
Reply:
Yasuji Arase – 28 May 2009
The pineapple upside‐down liver cake
Anthony W. Castleberry, David A. Geller, Allan Tsung – 28 May 2009
Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease
Kerry‐Lee Milner, David van der Poorten, Aimin Xu, Elisabetta Bugianesi, James G. Kench, Karen S. L. Lam, Donald J. Chisholm, Jacob George – 28 May 2009 – Several circulating cytokines are increased with obesity and may combine with the influence of visceral fat to generate insulin resistance, inflammation, and fibrosis in nonalcoholic fatty liver disease (NAFLD).
Novel mechanism of C‐reactive protein for enhancing mouse liver innate immunity
Akihito Inatsu, Manabu Kinoshita, Hiroyuki Nakashima, Jun Shimizu, Daizoh Saitoh, Seiichi Tamai, Shuhji Seki – 28 May 2009 – Although C‐reactive protein (CRP) is a representative acute‐phase protein produced by hepatocytes, the role of CRP in liver innate immunity remains unclear.
Increased donor risk: Who should bear the burden?
Sandy Feng – 28 May 2009
Donor livers with steatosis are safe to use in hepatitis C virus–positive recipients
- Read more about Donor livers with steatosis are safe to use in hepatitis C virus–positive recipients
Patrizia Burra, Massimiliano Loreno, Francesco Paolo Russo, Giacomo Germani, Alessandra Galligioni, Marco Senzolo, Umberto Cillo, Giacomo Zanus, Stefano Fagiuoli, Massimo Rugge – 28 May 2009 – Whether donor graft steatosis affects liver function and influences survival after liver transplantation is still open to debate. The aim of this study was to assess the impact of donor graft steatosis on long‐term liver histology after liver transplantation.
Long‐term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA
Jung Im Seok, Dong Kuck Lee, Chang Hyeong Lee, Min Su Park, Sun Young Kim, Hyang‐Sook Kim, Hee‐Young Jo, Chang Hun Lee, Dae‐Seong Kim – 28 May 2009 – Clevudine (Revovir), a pyrimidine nucleoside analogue, is a recently introduced antiviral drug. Clinical trials have demonstrated potent, sustained antiviral activity against hepatitis B virus without specific adverse events. The lack of cytotoxicity and absence of an effect on mitochondrial function have been considered the reasons for the fewer adverse events.
Hepatic stellate cells express functional CXCR4: Role in stromal cell–derived factor‐1α–mediated stellate cell activation
Feng Hong, Ana Tuyama, Ting Fang Lee, Johnny Loke, Ritu Agarwal, Xin Cheng, Anita Garg, M. Isabel Fiel, Myron Schwartz, Jose Walewski, Andrea Branch, Alison D. Schecter, Meena B. Bansal – 28 May 2009 – Chemokine interactions with their receptors have been implicated in hepatic stellate cell (HSC) activation. The hepatic expression of CXCR4 messenger RNA is increased in hepatitis C cirrhotic livers and plasma levels of its endogenous ligand, stromal cell–derived factor‐1α (SDF‐1α), correlate with increased fibrosis in these patients. The expression of CXCR4 by HSCs has not been reported.